Casper Breum is Director at Spero Therapeutics, Inc. (SPRO). They have made 1 open-market trade across 1 company since 2017, most recently 2017-11-06.
CIK 0001630850
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $3.0M since 2017, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SPRO | 289,102 | $318K |
Shares reported on the most recent Form 4, priced at the 2017-11-07 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SPRO | BUY | 2017-11-06 | 2017-11-07 | $14.00 | $3.0M | +15.7% | -16.1% | -5.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.